Half-year Report 2023

Financial ReportInterim consolidated statement of changes in equity

Interim consolidated statement of changes in equity

1 January - 30 June (unaudited)
Attributable to shareholders of PolyPeptide Group AG:


kEUR	Share capital	Share premium	Translation reserve	Treasury shares	Other capital reserves	Retained earnings	Total

Balance as at 1 January 2023	302	203,129	14,119	-13,609	3,590	214,146	421,677

Result for the period						-34,266	-34,266
Remeasurement gain / (loss) on defined benefit plans, net of tax						2,231	2,231
Currency exchange differences			-5,720				-5,720
Total comprehensive income	–	–	-5,720	–	–	-32,035	-37,755

Purchase of own shares							–
Dividends paid							–
Share-based payment					393		393
Transfer of own shares				1,327	-1,327		–
Total transactions with owners	–	–	–	1,327	-934	–	393
Balance as at 30 June 2023	302	203,129	8,399	-12,282	2,656	182,111	384,315

Interim consolidated statement of changes in equity (continued)

1 January - 30 June (unaudited)
Attributable to shareholders of PolyPeptide Group AG:


kEUR	Share capital	Share premium	Translation reserve	Treasury shares	Other capital reserves	Retained earnings	Total

Balance as at 1 January 2022	302	212,800	9,285	-1,187	3,946	196,028	421,174

Result for the period						10,247	10,247
Remeasurement gain / (loss) on defined benefit plans, net of tax						7,690	7,690
Currency exchange differences			8,840				8,840
Total comprehensive income	–	–	8,840	–	–	17,937	26,777

Purchase of own shares				-11,962			-11,962
Dividends paid		-9,671					-9,671
Share-based payment					991		991
Transfer of own shares				188	-188		–
Total transactions with owners	–	-9,671	–	-11,774	803	–	-20,642
Balance as at 30 June 2022	302	203,129	18,125	-12,961	4,749	213,965	427,309

Interim consolidated statement of financial position

Interim consolidated statement of cash flow

This website uses cookies to ensure you get the best experience on our website.Privacy statement